NOL3 and myalgic encephalomeyelitis/chronic fatigue syndrome: Traditionally used to treat chronic fatigue-related disorders, MYP exhibited moderate benefits in a recent phase 2 RCT with 98 ME/CFS patients, showing pronounced effectiveness for those with severe symptoms (Joung et al., 2019a).